### Cover Block
Amgen Inc. / AMGN / NASDAQ | Report date: 2025-07-02  
Last close $300.20 | Fair-Value Estimate $320.00 | Price/FVE 0.94 | Market Cap insufficient data  
Economic Moat Wide | Uncertainty rating Medium | Capital Allocation rating Standard  
Equity Style Box Large Core | Sector Healthcare | Industry Biotechnology | ESG Risk Rating summary insufficient data  

### Contents
- Analyst Note  
- Business Description  
- Business Strategy & Outlook  
- Bulls Say / Bears Say  
- Economic Moat  
- Fair Value and Profit Drivers  
- Risk & Uncertainty  
- Capital Allocation  
- Financials Snapshot  
- ESG Risk  
- Appendix  
- Sources  

### Analyst Note
Amgen Inc. reported strong financial results for the second quarter of 2025, with total revenues reaching $9.18 billion, representing a 9% increase year over year [1][2][3]. Adjusted earnings per share came in at $6.02, surpassing analyst expectations of $5.26 by 14.45% and marking a 21% rise from the prior-year period [2][4]. Net income for the quarter was $1.43 billion [1]. The results were driven by robust global demand for key products and successful new launches, with significant sales growth across the portfolio [3]. Amgen also issued improved full-year 2025 guidance and maintained its quarterly dividend at $2.38 per share while continuing its share buyback program [1]. Despite the beat, the stock declined 0.62% in after-hours trading to $300.20 [2].

This performance reinforces our positive thesis on Amgen as a leading biotechnology firm with a diversified product lineup and strong innovation pipeline. The 9% revenue growth highlights resilience in core segments like oncology and inflammation, bolstered by Phase 3 trial successes [5]. However, higher operating costs partially offset the revenue gains [4]. Looking ahead, the slightly raised 2025 outlook suggests confidence in sustained momentum from new product launches and pipeline advancements [1][4]. We view Amgen's focus on rare diseases and biosimilars as key drivers for medium-term growth, though competitive pressures in mature products remain a watch point.

Our fair value estimate of $320 implies modest upside from the current price, based on projected revenue CAGR of 6% over the next five years, stable margins, and a WACC of 7.5%. Risks include regulatory hurdles and patent expirations, but Amgen's financial health, with a score of 2.95 indicating good stability, supports our outlook [2]. Overall, the Q2 results update our thesis toward cautious optimism, emphasizing execution on pipeline milestones amid a competitive biopharma landscape. (312 words)

### Business Description
Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. It focuses on areas such as oncology, inflammation, bone health, cardiovascular disease, and nephrology. Key products include Enbrel for inflammation, Prolia for osteoporosis, and oncology drugs like Kyprolis and Blincyto. The company operates through segments including innovative medicines and biosimilars. Geographically, the majority of revenues come from the United States, with significant presence in Europe and Asia-Pacific [5].

### Business Strategy & Outlook
Amgen's competitive edge stems from its extensive portfolio of high-barrier biologics and a strong R&D pipeline targeting unmet needs in rare diseases and obesity. The company leverages its manufacturing expertise for biosimilars to capture market share from expiring patents, while investing in next-generation therapies like MariTide for obesity. Secular trends favoring biologics and personalized medicine play to Amgen's strengths, with global aging populations driving demand for bone and cardiovascular treatments [3][5].

In the medium term, Amgen is positioned for steady growth through product launches and acquisitions, such as the Horizon Therapeutics deal enhancing its rare disease focus. However, it faces headwinds from biosimilar competition eroding sales of legacy products like Neulasta. The outlook assumes 5-7% annual revenue growth through 2029, supported by pipeline successes, but dependent on regulatory approvals and market access [1][4].

Rising healthcare costs and value-based pricing models could pressure margins, yet Amgen's scale enables cost efficiencies. Overall, the strategy emphasizes innovation and diversification to navigate a maturing portfolio.

### Bulls Say / Bears Say
**Bulls Say**  
1. Strong Q2 revenue growth of 9% and EPS beat signal robust demand and pipeline potential [1][2].  
2. Raised 2025 guidance and ongoing buybacks reflect confidence in financial stability [1][4].  
3. Advances in diverse portfolio, including new launches, position Amgen for sustained market share gains [3].  

**Bears Say**  
1. Higher operating costs offset some revenue gains, potentially pressuring future margins [4].  
2. Stock declined post-earnings, indicating investor concerns over valuation or competition [2].  
3. Dependence on mature products risks erosion from generics and biosimilars.

### Economic Moat
Amgen possesses a wide economic moat primarily from intangible assets, including patents and regulatory exclusivity on its biologics portfolio. Products like Enbrel and Prolia benefit from high switching costs and complex manufacturing, deterring competition [5]. Evidence includes consistent revenue from these franchises despite market challenges, with Q2 2025 sales growth underscoring durability [3]. Cost advantages arise from scale in R&D and production, enabling lower unit costs for biosimilars.

### Fair Value and Profit Drivers
Our discounted cash flow model projects revenue CAGR of 6% from 2025-2029, driven by 9% Q2 growth and raised guidance implying full-year revenues around $35 billion [1][4]. We assume operating margins improving to 35% by 2029 from current levels, reflecting cost controls amid higher expenses [4]. WACC is 7.5%, incorporating a beta of 0.8 and equity risk premium of 5%.

EPS bridge: 2025 EPS estimated at $20.50 (from Q2 $6.02 and assumed quarterly progression) [2], growing to $25 by 2029. Terminal growth rate is 3%. This yields a fair value of $320, implying P/E multiple of 15.6x forward EPS and EV/EBITDA of 12x.

### Risk & Uncertainty
Macro risks include economic slowdowns reducing healthcare spending. Regulatory risks involve FDA delays for pipeline drugs or biosimilar approvals eroding revenues. ESG risks center on drug pricing scrutiny and access issues. Operational risks include supply chain disruptions and competition in obesity treatments. These factors contribute to medium uncertainty, potentially swinging valuation by 20-30%.

### Capital Allocation
Amgen maintains a solid balance sheet with strong cash flow generation [2]. M&A discipline is evident in targeted deals like Horizon. Dividend policy is consistent at $2.38 quarterly, yielding about 3.2% [1]. Buyback program is active without new issuances [1]. Overall rating: Standard.

### Financials Snapshot

| Metric         | 2022 Actual | 2023 Actual | 2024 Actual | 2025 Forecast | 2026 Forecast | 2027 Forecast | 2028 Forecast | 2029 Forecast |
|----------------|-------------|-------------|-------------|---------------|---------------|---------------|---------------|---------------|
| Revenue ($B)  | insufficient data | insufficient data | insufficient data | 35.0 | 37.1 | 39.3 | 41.7 | 44.2 |
| Op-Margin %   | insufficient data | insufficient data | insufficient data | 32.0 | 33.0 | 34.0 | 34.5 | 35.0 |
| EPS ($)       | insufficient data | insufficient data | insufficient data | 20.5 | 21.7 | 23.0 | 24.4 | 25.8 |
| FCF ($B)      | insufficient data | insufficient data | insufficient data | 10.0 | 10.6 | 11.2 | 11.9 | 12.6 |
| ROIC %        | insufficient data | insufficient data | insufficient data | 12.0 | 12.5 | 13.0 | 13.5 | 14.0 |

Note: Actuals for 2022-2024 omitted due to insufficient data; forecasts based on Q2 2025 trends and guidance [1][4].

### ESG Risk
Sustainalytics (or equivalent) score: insufficient data. Peer comparison: insufficient data. Material ESG issues include drug pricing ethics, access to medicines, and clinical trial transparency, potentially impacting reputation and regulation.

### Appendix
**Key Valuation Assumptions Table**

| Assumption     | Value  | Rationale |
|----------------|--------|-----------|
| Revenue CAGR 2025-2029 | 6.0%  | Based on Q2 growth and guidance [1][4] |
| Terminal Growth Rate | 3.0%  | Long-term industry average |
| WACC          | 7.5%  | Beta 0.8, risk-free rate 4% |
| Op-Margin 2029 | 35.0% | Efficiency improvements |

**Glossary of Ratings**  
- Economic Moat: Wide (durable competitive advantage).  
- Uncertainty: Medium (moderate valuation sensitivity).  
- Capital Allocation: Standard (adequate stewardship).

### Sources
[1] Simply Wall St – “Did Strong Q2 Results and Upbeat Guidance Just Shift Amgen's (AMGN) Earnings Outlook?”, Simply Wall St News, 2025-08-09, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/did-strong-q2-results-and-upbeat-guidance-just-shift-amgens  
[2] Investing.com – “Earnings call transcript: Amgen beats Q2 2025 earnings expectations”, Investing.com, 2025-08-05, https://www.investing.com/news/transcripts/earnings-call-transcript-amgen-beats-q2-2025-earnings-expectations-93CH-4171634  
[3] Yahoo Finance – “Amgen Inc (AMGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Robust Pipeline ...”, Yahoo Finance, 2025-08-06, https://finance.yahoo.com/news/amgen-inc-amgn-q2-2025-072626063.html  
[4] TradingView – “Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly”, TradingView News, 2025-08-06, https://www.tradingview.com/news/zacks:4b9ce1cd4094b:0-amgen-s-q2-earnings-sales-beat-estimates-2025-view-raised-slightly/  
[5] Amgen Inc. – “AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS”, Amgen Inc., 2025-05-01, https://investors.amgen.com/news-releases/news-release-details/amgen-reports-first-quarter-2025-financial-results/  

This analysis is for informational purposes only and is not a recommendation to buy or sell any security.